Clinical Trials Logo

Clinical Trial Summary

The investigators will conduct an 8-week, non-randomized, open-label study of brexpiprazole in 20 persons with bipolar I or II disorder, depressed mood state. Primary aim will be to assess if brexpiprazole is associated with a reduction in depressive symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS). Secondary aims will include an assessment of the following in patients with bipolar disorder taking brexpiprazole: manic symptoms, cognition, safety and tolerability of brexpiprazole, and quality of life.

Subjects will be discontinued from the study if any of the following conditions occurs: change in diagnosis to other than bipolar I or II disorder, development of active suicidal or homicidal ideation with plan and intent, worsening of mood symptoms, that in the opinion of the investigators requires discontinuation, pregnancy, development of severe life-threatening medical condition, involuntary psychiatric hospitalization or incarceration.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03427892
Study type Interventional
Source University of Texas Southwestern Medical Center
Contact
Status Completed
Phase Phase 4
Start date March 1, 2017
Completion date March 15, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Active, not recruiting NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Active, not recruiting NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Recruiting NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Recruiting NCT03658824 - Behavioural Activation for Bipolar Depression: A Case Series N/A
Not yet recruiting NCT03679962 - Triple Chronotherapy in Adolescents N/A
Not yet recruiting NCT03349528 - Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression Phase 2
Not yet recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1
Completed NCT00566150 - Levetiracetam in the Management of Bipolar Depression N/A
Not yet recruiting NCT03674671 - Ketamine Versus Electroconvulsive Therapy in Depression Phase 3
Completed NCT01284517 - Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression Phase 3
Completed NCT00988949 - Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release Phase 1